120-h Continuous Infusion of Ifosfamide Alone and in Combination with Cis-Platinurc in Children and Adolescents with Recurrent Ewing’s Sarcoma1

Bier, V.; Jürgens, H.; Etspüler, G.; Exner, Ulrich; Kühl, Jørgen Tobias; Ritter, J; Winkler, Kurt; Göbelb, U.

doi:10.1159/000429532

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the variability of ifosfamide metabolism with various treatment schemes having been documented, there is no clear evidence that the various methods of intravenous administration influence the risk of nephrotoxicity. Increased risk in the case of additional treatment with cisplatin appears to have been verified, even though the latter causes renal damage through a different mechanism, predominantly resulting in reduced glomerular filtration and loss of magnesium [29,33,40,[44][45][46]. In addition, aminoglicosides, frequently used with neutropenic patients, do not seem to represent an exacerbating factor in the development of ifosfamide-related renal damage [42].…”

Section: Ifosfamide-induced Nephrotoxicitymentioning

confidence: 99%

See 1 more Smart Citation

Renal toxicity and chemotherapy in children with cancer

Ruggiero

Ferrara

Attinà

et al. 2017

Brit J Clinical Pharma

View full text Add to dashboard Cite

The clinical use of antineoplastic drugs can be limited by different drug-induced toxicities. Of these, renal dysfunction may be one of the most troublesome in that it can be cumulative and in general is only partially reversible with the discontinuation of the treatment. Renal toxicity may be manifested as a reduction of the glomerular filtration rate, electrolyte imbalances, or acute renal failure. Careful assessment of renal function has to be performed taking into account that the impairment of renal function is initially silent and only later may be clinically dramatic. When clinically indicated, the reduction or, in cases of severe nephrotoxicity, the suspension of chemotherapy should be considered to avoid the progressive deterioration of the compromised glomerular and/or tubular function.

show abstract

Section: Ifosfamide-induced Nephrotoxicitymentioning

confidence: 99%

“…Other studies appear to confirm that tubular damage can progress even several months after cessation of therapy [29]. On the other hand, progression to chronic renal failure has been clearly documented in adults [44][45][46][47][48][49][50][51][52].…”

Section: Ifosfamide-induced Nephrotoxicitymentioning

confidence: 99%

Renal toxicity and chemotherapy in children with cancer

Ruggiero

Ferrara

Attinà

et al. 2017

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…A single dose for anti-cancer treatment with CP and IF is 0.7-2.8 g/m 2 body surface; and up to 60 g/m 2 body surface is common for whole treatment (Bier et al 1987;Fichtner and Nowak 1987;Allwood and Wright 1993). This corresponds to approx.…”

Section: Hazard Assessment: Usage Environmental Occurrence Fate Andmentioning

confidence: 99%

Estimation of the cancer risk to humans resulting from the presence of cyclophosphamide and ifosfamide in surface water

Kümmerer

Al‐Ahmad

2009

Environ Sci Pollut Res

View full text Add to dashboard Cite

CP and IF are carcinogens. With respect to newborn and children, reduction of the emission of CP and IF into effluent and surface water is recommended at least as a precautionary measure. The collection of unused and outdated drugs is a suitable measure. Collection of patients' excreta as a measure of input reduction is not recommended. Data suitable for the assessment of the risk for newborn and children should be collected in order to perform a risk assessment for these groups. This can stimulate discussion and give new insights into risk assessment for pharmaceuticals in the environment. Our study showed that in the long term, effective risk management for the reduction of the input of CP and IF are recommendable.

show abstract